Results 71 to 80 of about 3,987 (159)

Eosinophilic granulomatosis with polyangiitis developed during treatment with benralizmab for severe asthma: A case report and literature review

Respirology Case Reports
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare autoimmune disorder characterized by necrotizing vasculitis, asthma, and eosinophilia. We report a case of EGPA that developed during benralizumab treatment for severe asthma and provide a ...
Mitsukuni Sakabe, Kazunori Tobino, Yumi Obata, Shota Sogabe, Kazuki Uchida, Yosuke Murakami   +5 more
doaj   +1 more source

Real-world comparative effectiveness of biologic therapies in severe asthma: EU-ADVANTAGE

ERJ Open Research
Background In Europe, although multiple biologics have been approved for the treatment of severe asthma (SA), comparative data from real-world settings remain limited. This study compared the real-world effectiveness of dupilumab with that of omalizumab,
Giorgio Walter Canonica, Johann Christian Virchow, Arnaud Bourdin, Juby Jacob-Nara, Kinga Borsos, Richard H. Stanford, Zhixiao Wang, Mena Soliman, Lynn Huynh, Fariha Haque, Mei Sheng Duh, Wei-Han Cheng   +11 more
doaj   +1 more source

Benralizumab Reduces Respiratory Exacerbations and Oral Glucocorticosteroid Dose in Patients with Severe Asthma and Eosinophilic Granulomatosis with Polyangiitis

Journal of Asthma and Allergy
Carlo Mümmler,1 Pontus Mertsch,1 Michaela Barnikel,1 Frank Haubner,2 Ulf Schönermarck,3 Ulrich Grabmaier,4 Hendrik Schulze-Koops,5 Jürgen Behr,1 Nikolaus Kneidinger,1,6 Katrin Milger1 1Department of Medicine V, LMU University Hospital, LMU Munich ...
Mümmler C, Mertsch P, Barnikel M, Haubner F, Schönermarck U, Grabmaier U, Schulze-Koops H, Behr J, Kneidinger N, Milger K   +9 more
doaj  

Benralizumab in severe eosinophilic asthma: a comprehensive systematic review and meta-analysis of randomized controlled trials evaluating lung function, asthma control, and safety outcomes

Systematic Reviews
Background Benralizumab, a monoclonal antibody, targets eosinophils by blocking an interleukin-5 receptor, improving severe allergic asthma. Severe eosinophilic asthma affects about 10% of asthma patients and often requires high-dose corticosteroids ...
Abbas Al Mutair, Yasmine Alabbasi, Hanan F. Alharbi, Hanan Alyami, Haifa Mohmmed Al-Shammari, Abdullah Awad Al-Omari, Eman A. Bomozah, Faiza Aljarameez, Muhammad Daniyal   +8 more
doaj   +1 more source

Benralizumab as a steroid-sparing rescue therapy in ANCA-negative eosinophilic granulomatosis with polyangiitis: real-world experience from three cases and review of the literature. [PDF]

Rheumatol Int
Sebastian A, Kosałka-Węgiel J, Puchala M, Życińska K, Kolarz B, Bieniasz-Pawlik E, Korkosz M.   +6 more
europepmc   +1 more source

Biologic Switching in Patients with Severe Asthma: Effects on Exacerbations, Corticosteroid Use and Lung Function. [PDF]

J Clin Med
Dindar Çelik F, Aksu K.
europepmc   +1 more source

Biologic switching in allergic bronchopulmonary aspergillosis: a scoping review of published clinical experience. [PDF]

J Thorac Dis
Hu Q, Pan X, Chen R, Li G, Li Y, Zheng Y, Zhong Z, Zhang X, Chen Y, Ye J, Duan J, Li J.   +11 more
europepmc   +1 more source

A case of herpes zoster following the first dose of benralizumab. [PDF]

Allergol Select
Aksu K, Telli O, Yağdıran M, Dindar Çelik F, Çelik Tuğlu H, Göktürk Ö.   +5 more
europepmc   +1 more source

One size does not fit all: uncontrolled T2 inflammation on tezepelumab-a case series. [PDF]

Allergy Asthma Clin Immunol
Tardif A, Boulay ME, Côté A, Godbout K.   +3 more
europepmc   +1 more source

Safety and effectiveness of benralizumab in Indian patients with severe eosinophilic asthma: results from the FAST study. [PDF]

Front Med (Lausanne)
Talwar D, Maturu VN, Meshram PL, Mittal S, Praveen JV, Guleria R, Kumar A, Agarwal A, Verma AK, Mohan M, Narasimhan R, Jain N, Sharma R, Kumar R, Parakh U, Momi G.   +15 more
europepmc   +1 more source